Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX): 14 pipeline candidates · 12 upcoming catalysts · ~19 mo cash runway · 24 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
19.1 months
D/E 4.62 · 0% dilution
Lead: Approved
14 candidates
12 upcoming, next in ~13d
0 buys · 65 sells (180d)
A transparent, data-derived signal for Travere Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.1B
Cash
$78.4M
Quarterly Burn
$40.4M
Runway
19.1 mo
Revenue
$127.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| Baxdrostat and dapagliflozin | Phase 4 |
| Dapagliflozin | Phase 4 |
| Dapagliflozin 10Mg Tab | Phase 4 |
| Dapagliflozin along with standard medical therapy | Phase 4 |
| Dapagliflozin Propanediol | Phase 4 |
| FILSPARI | BLA Filed |
| FILSPARI® | Approved |
| Intensified medical follow-up and glucose-lowering drugs | Phase 3 |
| Irbesartan | Phase 3 |
| No sparsentan | Phase 4 |
Showing 10 of 14 candidates. Sign up for full pipeline.
Upcoming Catalysts (12)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
264
Total value held
$3.69B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 22,839,172 | $678.5M |
| fmr llc | 10,967,967 | $325.9M |
| perceptive advisors llc | 8,285,102 | $246.2M |
| vanguard capital management llc | 8,091,624 | $240.4M |
| blackrock, inc. | 7,792,033 | $231.5M |
| state street corp | 4,959,988 | $147.4M |
| armistice capital, llc | 4,897,417 | $145.5M |
| nomura asset management international inc. | 3,270,513 | $97.2M |
| kynam capital management, lp | 2,423,918 | $72.0M |
| geode capital management, llc | 2,369,559 | $70.4M |
Showing top 10 of 264 institutional holders of Travere Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Travere Therapeutics, Inc.'s pipeline?
Travere Therapeutics, Inc. (TVTX) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Travere Therapeutics, Inc.'s lead drug candidate?
Travere Therapeutics, Inc.'s most advanced tracked candidate is Baxdrostat and dapagliflozin (Phase 4) for Lung Adenocarcinoma.
What is Travere Therapeutics, Inc.'s next catalyst?
Travere Therapeutics, Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Single Dose, Randomized, Open-label, Two-way Crossover Food-effect Bioavailbility Study of Fixed D" — expected July 1, 2026.
What is Travere Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Travere Therapeutics, Inc. has approximately 19.1 months of cash runway.
What is Travere Therapeutics, Inc.'s market capitalization?
Travere Therapeutics, Inc.'s market capitalization is approximately $5.1B.
Get the full picture on Travere Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.